piracetam has been researched along with Kidney Diseases in 5 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levetiracetam was a probable cause of depression in these 2 elderly patients." | 7.75 | Probable levetiracetam-associated depression in the elderly: two case reports. ( Bainbridge, JL; Linnebur, SA; Vande Griend, JP, 2009) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Levetiracetam was a probable cause of depression in these 2 elderly patients." | 3.75 | Probable levetiracetam-associated depression in the elderly: two case reports. ( Bainbridge, JL; Linnebur, SA; Vande Griend, JP, 2009) |
| " This review examines strategies to overcome ARC and summarizes current pharmacokinetic and pharmacodynamic literature in patients with ARC in an effort to provide dosing guidance for this patient population." | 2.52 | Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics. ( Daley, MJ; Hobbs, AL; Roberts, KM; Shea, KM, 2015) |
| " Pharmacokinetic studies of levetiracetam have been conducted in healthy volunteers, in adults, children and elderly patients with epilepsy, and in patients with renal and hepatic impairment." | 2.42 | Clinical pharmacokinetics of levetiracetam. ( Patsalos, PN, 2004) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Levetiracetam is a novel orally active antiepileptic drug with a unique preclinical profile." | 2.41 | Pharmacokinetic profile of levetiracetam: toward ideal characteristics. ( Patsalos, PN, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hobbs, AL | 1 |
| Shea, KM | 1 |
| Roberts, KM | 1 |
| Daley, MJ | 1 |
| Vande Griend, JP | 1 |
| Linnebur, SA | 1 |
| Bainbridge, JL | 1 |
| Patsalos, PN | 2 |
| Briggs, DE | 1 |
| French, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study[NCT00242606] | Phase 3 | 409 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for piracetam and Kidney Diseases
| Article | Year |
|---|---|
Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.
Topics: Anti-Bacterial Agents; Creatinine; Critical Illness; Drug Administration Schedule; Humans; Kidney Di | 2015 |
Clinical pharmacokinetics of levetiracetam.
Topics: Adult; Aged; Anticonvulsants; Chemical Phenomena; Chemistry, Physical; Child; Drug Interactions; Dru | 2004 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
1 other study available for piracetam and Kidney Diseases
| Article | Year |
|---|---|
Probable levetiracetam-associated depression in the elderly: two case reports.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Depression; Epilepsies, Partial; Female; | 2009 |